In:
Cancer, Wiley, Vol. 126, No. 10 ( 2020-05-15), p. 2279-2287
Abstract:
Using Center for International Blood and Marrow Transplant Research registry data, we demonstrate that in diffuse large B cell lymphoma patients undergoing autologous hematopoietic cell transplantation, the addition of rituximab to the BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen has no impact on survival outcomes after transplantation.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink